Want to see SE:SPAGO full AI Analyst Report?
Spago Nanomedical AB (SPAGO) Stock Statistics & Valuation Metrics
Total Valuation
Spago Nanomedical AB has a market cap or net worth of SEK 27.46M. The enterprise value is SEK 44.74M.
- Market Cap
- SEK 27.46M
- Enterprise Value
- SEK 44.74M
Share Statistics
Spago Nanomedical AB has 798,380,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 798,380,100
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Spago Nanomedical AB’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -97.93%.
- Return on Equity (ROE)
- -0.86
- Return on Assets (ROA)
- -0.72
- Return on Invested Capital (ROIC)
- -97.93%
- Return on Capital Employed (ROCE)
- -0.98
- Revenue Per Employee
- 72.83K
- Profits Per Employee
- -4.43M
- Employee Count
- 6
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Spago Nanomedical AB is -0.74. Spago Nanomedical AB’s PEG ratio is -0.01.
- PE Ratio
- -0.74
- PS Ratio
- 694.59
- PB Ratio
- 0.73
- Price to FCF
- -1.65
- Price to Operating Cash Flow
- -1.06
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Spago Nanomedical AB had revenue of 437.00K and earned -26.55M in profits. Earnings per share was -0.07.
- Revenue
- 437.00K
- Gross Profit
- -19.38M
- Operating Income
- -30.86M
- Pretax Income
- -26.55M
- Net Income
- -26.55M
- EBITDA
- -26.39M
- Earnings Per Share (EPS)
- -0.07
Cash Flow
In the last 12 months, operating cash flow was -21.86M and capital expenditures 14.48M, giving a free cash flow of -16.82M billion.
- Operating Cash Flow
- -21.86M
- Free Cash Flow
- -16.82M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Spago Nanomedical AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -60.54%
- Earnings Yield
- -113.91%
Stock Price Statistics
- Beta
- 1.21
- 52-Week Price Change
- -76.39%
- 50-Day Moving Average
- 0.10
- 200-Day Moving Average
- 0.11
- Relative Strength Index (RSI)
- 21.80
- Average Volume (3m)
- 942.18K
Important Dates
Spago Nanomedical AB upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Spago Nanomedical AB as a current ratio of 6.96, with Debt / Equity ratio of 0.00%
- Current Ratio
- 6.96
- Quick Ratio
- 6.96
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.12
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Spago Nanomedical AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Spago Nanomedical AB EV to EBITDA ratio is 0.17, with an EV/FCF ratio of 0.28.
- EV to Sales
- -118.11
- EV to EBITDA
- 0.17
- EV to Free Cash Flow
- 0.28
- EV to Operating Cash Flow
- 0.22
Balance Sheet
Spago Nanomedical AB has SEK 32.51M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 32.51M billion.
- Cash & Marketable Securities
- SEK 32.51M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 32.51M
- Net Cash Per Share
- SEK 0.04
- Tangible Book Value Per Share
- SEK 0.05
Margins
Gross margin is -46335.00%, with operating margin of -81622.50%, and net profit margin of -65710.00%.
- Gross Margin
- -46335.00%
- Operating Margin
- -81622.50%
- Pretax Margin
- -65710.00%
- Net Profit Margin
- -65710.00%
- EBITDA Margin
- -71247.50%
- EBIT Margin
- -71437.50%
Analyst Forecast
The average price target for Spago Nanomedical AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -97.37%
- EPS Growth Forecast
- 25.28%
Scores
- Smart Score
- ―
- AI Score
- 43
